Identification Sixteen Metabolic Genes as Potential Biomarkers
for Colon Adenocarcinoma
Abstract Purpose Colon adenocarcinoma (COAD) is the most common
primary malignant tumor of the digestive tract. It is still important to
find important markers that affect the prognosis of COAD. This research
aims to identify some key prognosis-related metabolic genes (PRMG) and
establish a clinical prognosis model for COAD patients. MethodWe used The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO)
to obtain gene expression profiles of COAD, and then identified
differentially expressed prognostic-related metabolic genes through R
language and Perl software, Through univariate Cox analysis and least
absolute shrinkage and selection operator (LASSO) Cox analysis to obtain
target genes, established metabolic genes prognostic models and risk
scores. Through COX regression analysis, independent risk factors
affecting the prognosis of COAD were analyzed, and Receiver Operating
Characteristic (ROC) curve analysis of independent prognostic factors
was performed and a nomogram for predicting overall survival was
constructed. Perform the consistency index (C-index) test and decision
curve analysis (DCA) on the nomogram, and use Gene Set Enrichment
Analysis (GSEA) to identify the Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway of model genes. Result We selected PRMG based on
the expression of metabolic genes, and used LASSO Cox regression to
construct 16 metabolic gene (SEPHS1, P4HA1, ENPP2, PTGDS, GPX3, CP,
ASPA, POLR3A, PKM, POLR2D , XDH, EPHX2, ADH1B, HMGCL, GPD1L and MAOA)
models. The risk score generated from our model can well predict the
survival prognosis of COAD. A nomogram based on the clinicopathological
characteristics and risk scores of COAD can personally predict the
overall survival rate of COAD patients. Conclusion We
comprehensively identified metabolic genes related to the prognosis of
COAD. The risk score based on the expression of 16 metabolic genes can
effectively predict the prognosis of patients with COAD.